Table 4.

Patient and tumour characteristics in the 2nd line endocrine setting (n = 6)

Variable -2nd line	n (%), median (range)
Median age at AI initiation	56 years (40–74)
Performance status
0	2 (33%)
1	4 (67%)
Menopausal status
Premenopausal	1 (17%)
Postmenopausal	5 (83%)
Number of co-morbidities
0-1	5 (83%)
2-3	1 (17%)
Sites of metastases at time of AI initiation
Lung	4 (67%)
[Lung as only site of metastases]	4 (67%)
Peritoneum/pelvis	2 (33%)
Tumour volume at time of AI initiation
Low	2 (33%)
High	4 (67%)
Histological grade (Stanford)
Low	5 (83%)
High	1 (17%)
Hormone receptor status
ER
Moderate to strong (grade 2–3)	5 (83%)
Weak (grade 1)	1 (17%)
PgR
Moderate to strong (grade 2–3)	4 (67%)
Weak (grade 1)/ NA	2 (33%)
ER and PgR
Moderate to strong (grade 2–3)	4 (67%)
Weak (grade 1)	1 (17%)
% ER staining
>90%	5 (83%)
unknown	1 (17%)
% PgR staining
>90%	2 (33%)
>50%	3 (50%)
0%	1 (17%)
unknown	2 (33%)

AI, aromatase inhibitor; ER, oestrogen receptor; PgR, progesterone receptor.